



PRIMA BIOMED

Nasdaq: PBMD, ASX:PRR



2015 Capital Raising Presentation

19 May 2015
Marc Voigt (CEO) and Stuart Roberts (Global Head of IR)
www.primabiomed.com.au

Immuno-Oncology: A cancer treatment Revolution

Our LAG-3 programs: An important part of the Revolution

Beneficiaries: Patients...and our shareholders

Notice: Forward Looking Statements³

The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Prima BioMed – Who are we?

- **A cancer drug development company** focused on **immunology**, a revolutionary new field of cancer treatment
- Our original product, CVac™, is a cancer vaccine with favourable clinical data in second-remission ovarian cancer
- After acquiring Paris-based Immutep (completed Dec. 2014), and attracting A\$15m in new capital (announced May 2015) we are now focused on the immune checkpoint receptor **LAG-3**, where we are a world leader
- Multiple partners including **GSK** and **Novartis**

A TRANSFORMATIVE CAPITAL RAISING

19 May 2015 Capital Raising
Presentation Marc Voigt (CEO) and
Stuart Roberts (Global Head of IR)
www.primabiomed.com.au



Nasdaq: PBMD, ASX:PRR

Prima plans to raise A\$20m

- **Ridgeback Capital Investments**, a US-based specialist healthcare investor, is investing A\$15m in Prima
- Ridgeback has taken an immediate placement of ~72 million Prima shares at 1.73 cents per share, worth approx. A\$1.25m
- Ridgeback will invest the remainder of its A\$15m commitment via 3% convertible promissory notes which convert, at Ridgeback's election, into Prima ordinary shares at 2.00 cents per share
- Prima Board currently considering an SPP to shareholders which could yield another A\$5m
- Bergen funding arrangement to be mutually terminated

Significant cash reach achieved

7

- Proceeds fund two new clinical trials with Prima's lead product, IMP321 (soluble recombinant LAG-3)
 - * A Phase IIb chemo-immunotherapy trial of IMP321 together with paclitaxel to treat metastatic breast cancer in patients ineligible for Herceptin®
 - * A Phase I trial of IMP321 together with an immune checkpoint inhibitor
- Pending shareholder approval of Ridgeback's A\$15m investment, Prima can make significant progress with its LAG-3 programs, both existing and new
- Estimated cash reach to late 2016

A transformative capital raise

- Ridgeback is a highly regarded and fundamentally oriented investor in established and emerging healthcare companies
- Ridgeback, which knows immuno-oncology very well, to name new Prima director
- Ridgeback due diligence represents strong validation of Prima's strategy for immuno-oncology and LAG-3
- **Ridgeback's investment has a fixed price**, ie 1.73 cents for its initial placement and 2.00 cents per share for the convertible promissory notes
- Extraordinary General Meeting of Prima shareholders will be held in due course to approve Ridgeback's investment

PRIMA BIOMED TODAY – A LEADING IMMUNO-ONCOLOGY COMPANY



19 May 2015 Capital Raising
Presentation Marc Voigt (CEO) and
Stuart Roberts (Global Head of IR)
www.primabiomed.com.au



Nasdaq: PBMD, ASX:PRR

Prima BioMed today...

= Immuno-oncology –

Probably the most important field of cancer drug development today

= LAG-3 – An increasingly important immuno-oncology target, which we dominate

= Shareholder value as the market recognises the value of our products

LAG-3* both inhibits and activates immune response


11

* The Lymphocyte Activation Gene 3 product



- On the surface of T cells, can **inhibit** them from killing cancer cells

- Our soluble LAG-3 (sLAG) can **activate** the immune system to kill cancer cells by binding to molecules on APCs called MHC Class II, activating those molecules to present antigen to T cells




Three significant partners




Our partners



Cancer



Autoimmune diseases




Cancer



IMP321* doubled response rate in metastatic breast cancer Phase IIa

*Soluble LAG-3 (sLAG)



- PRR believes IMP321 will work in combination with other immune checkpoint regulators and other chemotherapies
- Randomised, placebo-controlled Phase IIb study will start in 2015
- Pilot Phase I study in an immunology combination will start in Q4 2015



GSK2831781* to treat autoimmune diseases

14

*LAG-3 depleting antibody - GSK2831781 is based on Immuteq's original IMP731 antibody

- Dec. 2010: **GlaxoSmithKline** licensed from Immuteq the right to develop LAG-3 depleting antibodies for autoimmune disease - £64m total deal package (~A\$124m as at 13 May 2015)
- Jan. 2015: PRR announced single-digit million dollar milestone for GSK's Phase I trial commencement
- GSK's investigational product aims to kill the few activated LAG-3+ T cells that are auto-reactive in autoimmune disease, leading to long term disease control



IMP701* brings Novartis into the LAG-3 camp

* Antagonist (ie blocking) anti-LAG-3 antibody


- 2012: US biotech CoStim licensed LAG-3 antagonists for cancer from Immutep

- Feb. 2014: **Novartis** bought CoStim for undisclosed sum

- History: Novartis persevered with Gleevec[®] - today a super-blockbuster

Our basic CVac thesis seems correct

CVac Hazard Ratio = 0.17 for second remission ovarian cancer



- **Thesis:** Mannan+MUC1* will generate tumour-destroying immune response in ovarian cancer

Evidence Progression-Free Survival: Nov. 2014, 8 month advantage for second remission patients (CAN-003 study, n=20, treatment 12.9 months, control 4.9 months, p=0.04)

- **Evidence Overall Survival:** May 2015, at least 16 month advantage (CAN-003 second remission treatment median not reached at 42 months, control median 25.5 months, p=0.07)

* Mannan is a sugar taken up by Antigen Presenting Cells, the orchestrators of the immune system. MUC1 is a protein overexpressed on many cancer cells.

WHY INVESTORS SHOULD LOOK AT PRIMA AGAIN




19 May 2015 Capital Raising
Presentation Marc Voigt (CEO) and
Stuart Roberts (Global Head of IR)
www.primabiomed.com.au



Nasdaq: PBMD, ASX:PRR

Until recently, the market hasn't liked us much (Oct. '14 – May. '15)

18




- Concerns over cash reduction from Immutep acquisition and need for more capital
- Lack of familiarity with Immutep programs
- Disappointment regarding the cessation of CVac clinical recruitment (Feb. 2015)
- Uncertain market for Life Sciences stocks in Australia

Six reasons why investors should look again

19

- Depth: We are now a multi-product company
- Important market space. Immuno-oncology is the most important area of cancer R&D today.
- Superior technology: With LAG-3, we are in a strong position within the emerging immuno-oncology drug class
- Partnerships: GSK, Novartis and Eddingpharm collaborations have potential to deliver mid-term milestones
- Leadership: Strong board and management plus impressive clinical and scientific advisors
- Funding: Prima's 2Q2015 capital raising funds commencement of two important clinical studies

Prima is one of the least expensive of our peer group



Potential for great news flow ...

21

- GSK milestone reached ✓
- MTA with NEC and Yamaguchi ✓
- CAN-003 final Overall Survival data ✓
- Start of Phase IIb with IMP321
- Start of immuno-combination study with IMP321
- Start of Phase I for IMP701
- Continued expansion of intellectual property
- R&D for new products
- Ongoing: Business development



Thank you

Stuart Roberts, Global Head of IR
stuart.roberts@primabiomed.com.au
+61 (0) 447 247 909

Merci

Professor Frédéric Triebel, CSO
frederic.triebel@primabiomed.com.au

Danke

Marc Voigt, CEO
marc.voigt@primabiomed.com.au



Nasdaq: PBMD, ASX:PRR

Our stock

23

- **Current market cap:** A\$50.5m (as at 19 May 2015)
- **Current share price:** 3.4 cents (AUD)
- **Shares on issue, pre Ridgeback (ASX: PRR):** 1.48 billion
- **Listed options on issue (ASX: PRRO),** 77.4 million (5.6% of current issued capital), exercisable at 20 cent by 19/6/2017
- **Unlisted options:** 226.5 million (16.3% of current issued capital), average exercise price 5.44 cents (AUD), average expiry date 7/10/2018
- **Turnover:** ASX, 2.9 million shares per day; Nasdaq, 25,000 ADRs per day (last 12 months average)
- **ISIN:** US745154B2034
- **Share ratio for ADRs traded on Nasdaq:** 1:30 (Depositary is BNY Mellon, Nasdaq: PBMD)
- **ADRs outstanding as at 15 May 2015:** 2.8 million (5.7% of capital)
- **ADRs potentially available for trade on Nasdaq:** 49.5 million
- **Registered shareholders as at May 2015-** ~12,300
- **Substantial shareholders (ie >5%):** None.